Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Zevra Therapeutics, Inc.’s reported figures.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s EBIT?
- Zevra Therapeutics, Inc. (ZVRA) reported EBIT of $16.78M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s EBIT changed year-over-year?
- Zevra Therapeutics, Inc.'s EBIT increased by 123.6% year-over-year, from -$71.04M to $16.78M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s EBIT has grown at a 64.3% compound annual growth rate (CAGR), from $7.91M to -$57.64M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Zevra Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude